Nevro And Medtronic Announce FDA Approval Of Spinal Cord Stimulation Label Expansions
Executive Summary
The FDA approved a diabetic peripheral neuropathy indication for Medtronic’s Intellis and Vanta spinal cord stimulators a few days after expanding the indication for Senza Nevro’s spinal cord stimulation system to include non-surgical refractory back pain.
You may also be interested in...
News We're Watching: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients
This week, studies supported Nevro’s spinal cord stimulation therapy and a VRx system that helps reduce pain; the American Medical Association found inconsistent insurance coverage of digital therapeutics; and Geneticure announced a cheek-swab test to identify which patients are most likely to benefit from renal denervation.
Minute Insight: FDA Approves Abbott’s SCS For Non-Surgical Back Pain
The approval, supported by the results of the randomized DISTINCT trial, includes all of Abbott’s spinal cord stimulation devices that deliver the proprietary BurstDR waveform.
Exec Chat: Medtronic Neuromodulation Approaches Inflection Point
Medtech Insight talked to Ashwini Sharan, the new chief medical officer for Medtronic's neuromodulation business, and and Nnamdi Njoku, the president of the business, to learn about the company's vision for neuromodulation technology and how the company can leverage its particular strengths make these therapies more effective and accessible.